An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors

Penetrating Auditory Brainstem Implant for Neurofibromatosis 2

NCT00030043CI-TRIAL-00017266completedPhase 1ClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

This is a study to gather some information on the safety and efficacy of the penetrating auditory brainstem implant (PABI) in patients with neurofibromatosis type 2.

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Neurofibromatosis 2	—	UNRESOLVED	—

Interventions

Interventions (1)

Intervention	Type	Mapped drug	Match
Penetrating auditory brainstem implant	Device	—	UNRESOLVED

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 18 Years

Show eligibility criteria text

Inclusion criteria:

* Diagnosis of neurofibromatosis type 2
* Speak English as a primary language

Exclusion criteria:

* Physical, psychological, or medical conditions that contraindicate the surgical procedure

References

Publications (0)

Data not yet available

No reference posted for this study.

Registry

Dates and enrollment

Start: Sep 1, 2001
Primary completion: —
Completion: Aug 1, 2003
First posted: Jan 31, 2002
Last update posted: Mar 25, 2015
Enrollment: 10
Lead sponsor: FDA Office of Orphan Products Development FED
Keywords: Electric Stimulation, Implants, Artificial, Brainstem, Electrodes, Speech Perception

Data updated 22 days agoSource updated Mar 25, 2015source: clinicaltrials

Locations

Locations by country (3)

Country	Sites	Recruiting
United States	3	0

Trial listing is informational. Eligibility is decided by the study team; contact information is on ClinicalTrials.gov.